Skip to content

Vacuum Assisted Closure as a Treatment for Open Fractures

Vacuum Assisted Closure as a Treatment for Open Fractures

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00582361
Acronym
VAC-OF
Enrollment
63
Registered
2007-12-28
Start date
2001-06-30
Completion date
2010-01-31
Last updated
2013-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Orthopaedic Traumatic Open Fractures

Keywords

Open Fractures, Vacuum Assisted Closure (VAC) device, Irrigation and Debridement

Brief summary

This project is designed as a prospective, randomized, comparative study evaluating the use of a negative pressure vacuum device in treating traumatic wounds sustained associated with an open fracture.

Detailed description

Soft tissue injury following an open fracture is a significant problem following surgical treatment of traumatic skeletal injuries. The soft tissue injury results from a combination of the initiating trauma and additional tissue injury during surgery. Current treatment includes open reduction and internal fixation versus external fixation, irrigation and debridement following admission, decreased activity (non weight bearing status on the injured extremity), maintaining the patient as an inpatient in the hospital, repeated irrigation and debridements (36-72 hours following the initial trauma) with concomitant wound culturing until which time it is determined that either delayed primary closure, or skin grafting with/without flap coverage should be attempted. All patients in the study will be treated with the appropriate empiric antibiotic regimen until wound culture results justify modification for antibiotic sensitivity/resistance reasons. In general, barring patient allergy, the empiric antibiotic regimen will adhere to the Gustilo and Anderson classification as follows: Grade I : Ancef Grade II : Ancef and Gentamicin or Zosyn Grade III : Ancef, Gentamicin or Zosyn, and add a Penicillin for grade IIIB open fractures. All wounds will be assessed initially at admission following the Gustilo and Anderson classification for open fractures. Subsequent wound assessments in the operating room will be graded according to the following descriptive scale: Type A wound: Abundant granulation tissue, ready for closure. Type B Wound: Granulation tissue present but inadequate for closure, Wound is clinically clean appearing. Type C Wound: No granulation tissue, no gross purulence. Type D Wound: Gross purulence/infected wound, no granulation tissue. The outcome variables consist of the intraoperative and postoperative adverse device effects recorded in the medical record and on the study data collection form, time to wound closure, intraoperative and postoperative complications recorded in medical record and on the study data collection form. Clinical photographs of the wounds will be taken with a digital camera at the time of admission to the study, and during each subsequent trip to the operating room (every 48-72 hours). We will also record the injury severity score for all multiple trauma patients recorded at the time of injury in the medical record and on the study data collection form, and soft tissue score according to Gustillo and Anderson for open injuries in the medical record and on the study data collection form. Baseline serum albumin and total lymphocyte counts will be taken on admission to evaluate baseline nutritional and immunologic status at the time of injury. All patients in the Intensive Care Units will have daily weights, fluid balances, and nutritional intake documented. Resuscitation data will also be recorded from the trauma room, including fluids, blood, and base deficit. The effects will be measured by clinical examination and will be augmented with culture data for any wounds that require surgical intervention. Patients who have an open fracture and who give informed consent to enter the study will be randomized into two groups. Group A will be patients treated with a return to the operating room approximately 48 hours following the initial trauma, and approximately every 48 hours thereafter, for irrigation and debridement and concomitant wound cultures (qualitative and quantitative) until which time the wound is judged by the surgeon to be ready for either delayed primary closure or flap/skin graft coverage. Group B will be patients treated with a VAC negative pressure device following the initial surgical irrigation and debridement. Group B patients will return to the operating room approximately 48 hours following the initial irrigation and debridement for VAC removal, wound cultures (qualitative and quantitative), repeat irrigation and debridement, and wound evaluation by the surgeon for possible delayed closure versus reapplication of the VAC device. Group B patients will also be returned to the operating room approximately every 48 hours thereafter for irrigation and debridement and concomitant wound cultures (qualitative and quantitative) until the wound is judged ready for coverage or closure by the surgeon.

Interventions

Group A patients will have a standard dressing applied following initial treatment of their open fracture. They will return to the operating room approximately 48 hours following the initial trauma, and approximately every 48 hours thereafter, for irrigation and debridement and concomitant wound cultures (qualitative and quantitative) until such time as the wound is judged by the surgeon to be ready for either delayed primary closure or flap/skin graft coverage.

DEVICEVAC

Group B patients will have a Vacuum Assisted Closure (VAC) device applied following initial treatment of their open fracture. They will return to the operating room approximately 48 hours following the initial trauma, and approximately every 48 hours thereafter, for irrigation and debridement and concomitant wound cultures (qualitative and quantitative) until such time as the wound is judged by the surgeon to be ready for either delayed primary closure or flap/skin graft coverage.

Sponsors

KCI USA, Inc
CollaboratorINDUSTRY
University of Alabama at Birmingham
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient who has sustained an open fracture that requires surgical irrigation and debridement. * No gross clinical evidence of infection.

Exclusion criteria

* A grossly infected open wound. Infection will be defined by clinical signs and symptoms of infection that include increasing drainage, increasing pain, purulent drainage, and increasing erythema. Any wounds that are thought to be infected will be cultured to confirm the diagnosis. * A surgical incision that can not be covered with VAC sponges and a water impermeable sheet (such as Ioban or Tegaderm) to achieve a closed vacuum environment over the wound. * Wounds associated with the surgical incision that are intentionally left open to heal with either a delayed primary closure or secondary granulation * Abnormal coagulation leading to an expanding hematoma that will require surgical debridement. * Pregnant women. * Inability or unwillingness to comply with protocol. * Patients or family members who are unable or unwilling to sign study informed consent.

Design outcomes

Primary

MeasureTime frameDescription
Healing of Orthopaedic Trauma Open Fracturesfrom surgery to wound closureHealing of the open wound following orthopaedic trauma open fracture surgery was measured in days. (The wound has healed adequately to permit closure)
InfectionsUp to 12 monthsNumber of acute, delayed and deep wound infections.

Countries

United States

Participant flow

Recruitment details

Patients admitted through the emergency department that met the criteria for the study were approached.

Participants by arm

ArmCount
Standard Dressing Group (1, A)
Group 1,A subjects will have a standard dressing applied following initial treatment of their open fracture.
25
Vacuum Assisted Closure Group (2, B)
Group 2,B subjects will have a Vacuum Assisted Closure (VAC) device applied following initial treatment of their open fracture.
38
Total63

Baseline characteristics

CharacteristicVacuum Assisted Closure Group (2, B)Standard Dressing Group (1, A)Total
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
3 Participants2 Participants5 Participants
Age, Categorical
Between 18 and 65 years
35 Participants23 Participants58 Participants
Age Continuous38 years
STANDARD_DEVIATION 15
44 years
STANDARD_DEVIATION 16
41 years
STANDARD_DEVIATION 15
Region of Enrollment
United States
38 participants25 participants63 participants
Sex: Female, Male
Female
10 Participants10 Participants20 Participants
Sex: Female, Male
Male
28 Participants15 Participants43 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 250 / 38
serious
Total, serious adverse events
1 / 254 / 38

Outcome results

Primary

Healing of Orthopaedic Trauma Open Fractures

Healing of the open wound following orthopaedic trauma open fracture surgery was measured in days. (The wound has healed adequately to permit closure)

Time frame: from surgery to wound closure

ArmMeasureValue (MEAN)
Standard Dressing Group (1, A)Healing of Orthopaedic Trauma Open Fractures3.2 use days
Vacuum Assisted Closure Group (2, B)Healing of Orthopaedic Trauma Open Fractures4.0 use days
Primary

Infections

Number of acute, delayed and deep wound infections.

Time frame: Up to 12 months

ArmMeasureValue (NUMBER)
Standard Dressing Group (1, A)Infections7 Number of infections
Vacuum Assisted Closure Group (2, B)Infections2 Number of infections

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026